“…This includes issues with hydroxychloroquine, lopinavir/ritonavir, remdesivir and ivermectin, with robust studies suggesting limited clinical benefit, although systematic reviews have suggested remdesivir can accelerate clinical improvement [ 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 ]. This is a concern as misinformation can increase morbidity, mortality and costs [ 50 , 51 , 52 , 53 ]. Concerns with misinformation have resulted in groups, including the World Health Organization (WHO) and the British Medical Journal (BMJ), providing evidence-based guidance [ 54 , 55 , 56 , 57 , 58 ].…”